In node-positive early-stage HR+ HER2-negative breast cancer patients, dose-dense chemotherapy has consistently demonstrated benefits that vary based on the composite measure of patients’ recurrence risk [23]. This evidence concerns the gene ERBB2 and breast carcinoma.